Endo Fights Investor's Cert. Bid In Opioid Stock-Drop Suit

Law360 (June 14, 2019, 2:13 PM EDT) -- Endo International PLC asked a Pennsylvania federal court Thursday to reject an institutional investor's class certification bid in a suit accusing the pharmaceutical company of hiding safety issues with an opioid drug, arguing the investor has little in common with the other stockholders.

Lead plaintiff SEB Investment Management AB had urged the court last month to certify a class of shareholders in the suit over a significant decline in share price when the opioid Opana was forcibly removed from the market.

But in a partially redacted motion on Thursday, Endo and its executives said the shareholder class should not be granted...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS